Day: March 14, 2022

NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR DISSEMINATION IN UNITED STATES CALGARY, Alberta, March 14, 2022 (GLOBE NEWSWIRE) — Pieridae Energy Limited (“Pieridae” or the “Company”) (PEA.TO) will release its fourth quarter and year-end 2021 results on Thursday, March 24, 2022 prior to markets opening. Chief Executive Officer Alfred Sorensen, Chief Operating Officer Darcy Reding and Interim Chief Financial Officer Adam Gray will discuss the financial results, Company developments and forward-looking strategy at 8:30 a.m. (MDT) /10:30 a.m. (EDT). Members of the investment community, shareholders and other interested parties are invited to participate by calling toll-free 1-877-800-8195, or international dial in 615-622-8082. Please dial in 10 minutes prior to the start of the call. No pass code is required. A live...

SAN DIEGO, March 14, 2022 (GLOBE NEWSWIRE) — Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today announced the appointment of Caren Deardorf to the company’s board of directors. Ms. Deardorf has broad experience in biotechnology, building on over 20 years at Biogen where she led commercial efforts for neurological diseases, including rare congenital disorders. Scott Struthers, Ph.D., founder and chief executive officer of Crinetics, stated, “Caren’s unique understanding of the importance of building commercial and corporate brands globally, while remaining focused on the needs of patients, was important to us, especially as we begin our transition...

Esposito Brings Strong Innovation and Electronics Solutions Business ExpertiseShyft Group – Carl Esposito The Shyft Group announced that Carl Esposito has been appointed to the Company’s Board of Directors, effective March 14, 2022.NOVI, Mich., March 14, 2022 (GLOBE NEWSWIRE) — The Shyft Group, Inc. (NASDAQ: SHYF), the North American leader in specialty vehicle manufacturing, assembly and upfit for the commercial, retail, and service specialty vehicle markets, today announced that Carl Esposito has been appointed to the Company’s Board of Directors, effective March 14, 2022. In addition, Ronald Harbour, 65, a member of the Shyft Board of Directors since 2009, will retire from the board effective as of the Company’s annual meeting of shareholders in May 2022. Esposito, 54, brings decades of experience in leading strategic...

— NUZYRA® (omadacycline) Generated Net U.S. Sales of $106.1 Million Comprised of $68.2 Million from the Core Commercial Business, a 76% increase over Prior Year, and $37.9 Million from the Initial Procurement of NUZYRA under the BARDA Bioshield Contract — Approval of NUZYRA in China for treatment of ABSSSI and CABP in December 2021; Triggered a $6 Million Milestone Payment from Zai Lab BOSTON, March 14, 2022 (GLOBE NEWSWIRE) — Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), today reported financial results and provided an update on corporate activities for the fourth quarter and full-year ended December 31, 2021. “We are extremely proud of the 76% year-over-year growth in the core NUZYRA commercial business despite continued challenges from the ongoing COVID-19 pandemic. Our performance this year reflects the important...

– 43% increase in the ratio of glycosylated alpha-dystroglycan (αDG) to total αDG from baseline were measured across all three dosing cohorts, signifying the oral therapy has the potential to address both the root cause of LGMD2i and drive functional improvements for patients– Average of 70% reduction in creatine kinase (CK), a key marker of muscle breakdown, after 90 days of treatment and average 77% reduction after 180 days– Increase in velocity in the 10-meter walk test (10MWT) at day 90 and 180, which is an improvement over the decline in velocity seen in the natural history data– If the development program is successful, BridgeBio believes BBP-418 could be the first approved therapy for the treatment of patients with LGMD2i– BridgeBio to host investor call on March 14, 2022 at 8:00 AM ET PALO ALTO, Calif.,...

Topline data from VIITAL™ expected in the third quarter of 2022 NEW YORK and CLEVELAND, March 14, 2022 (GLOBE NEWSWIRE) — Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that target enrollment has been achieved in its pivotal Phase 3 VIITAL™ study. The objective of VIITAL™ is to evaluate the safety and effectiveness of Abeona’s investigational EB-101 product for the treatment of recessive dystrophic epidermolysis bullosa (RDEB), a rare connective tissue disorder characterized by severe skin wounds that cause pain and can lead to systemic complications impacting the length and quality of life. Large chronic wounds typically do not heal spontaneously and inflict the greatest pain and clinical burden on RDEB patients. Large chronic wounds treated in VIITAL™ measured greater...

CHICAGO, March 14, 2022 (GLOBE NEWSWIRE) — Whole Earth Brands, Inc. (the “Company” or “we” or “our”) (Nasdaq: FREE), a global food company enabling healthier lifestyles through premium plant-based sweeteners, flavor enhancers and other foods, today announced its financial results for its fourth quarter and full year ended December 31, 2021. The Company also provided initial 2022 guidance. Full Year HighlightsReported consolidated revenue growth of 79%, including strategic acquisitions Branded CPG proforma organic constant currency revenue growth of approximately 12% on a two-year stacked basis versus 2019 and approximately 1% compared to 2020 Flavors & Ingredients revenue growth of approximately 7% compared to 2020 Operating income of $22.8 million and adjusted EBITDA of $82.2 million, an increase of approximately 51%Fourth...

Gilat’s SkyEdge IV Taurus modems enhance user experience of Intelsat’s global network with high-quality IFC for commercial aviation, regional aircraft, and business jets while leveraging interoperability with SkyEdge II-c PETAH TIKVA, Israel, March 14, 2022 (GLOBE NEWSWIRE) — Gilat Satellite Networks Ltd. (Nasdaq: GILT, TASE: GILT), a worldwide leader in satellite networking technology, solutions, and services, announced today that Intelsat is expanding its in-flight connectivity (IFC) capabilities with a strategic multimillion-dollar order for Gilat’s SkyEdge IV Taurus modems. SkyEdge IV Taurus is an ultra-high-performance modem for IFC designed to provide Wi-Fi internet and IPTV for passengers on commercial airlines, regional aircraft and business jets. Taurus is backward compatible, thus preserving past investments...

Company launches Precise™ Tumor test, part of a comprehensive suite combining germline, tumor and companion diagnostics in one easy-to-access solution SALT LAKE CITY, March 14, 2022 (GLOBE NEWSWIRE) — Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced the launch of Precise™ Oncology Solutions, a comprehensive offering designed to help oncologists determine effective and personalized treatment plans for individual patients. The new suite provides physicians with streamlined testing that combines germline testing, tumor profiling and companion diagnostic options including evaluation for Homologous Recombination Deficiency (HRD), an important cancer repair pathway. Precise Oncology Solutions includes Myriad’s new Precise™ Tumor Molecular Profile Test, developed in collaboration...